Extremely Low 90-Day Cardiac Device Infection Rates With TYRX Antibacterial Envelope Use

Published: May 13, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Use of TYRX, Inc.'s AIGISRx® Antibacterial Envelope reduced major infection rates by more than 90% in patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacement procedures compared to similar high-risk cohorts, according to the CITADEL & CENTURION clinical study results presented on Saturday at the Late Breaking Clinical Trials session at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions.

Hey, check out all the engineering jobs. Post your resume today!

Back to news